Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Confirmatory Study of BK1803 in Healthy Infants
NCT07793513Phase 3Not yet recruiting
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 3 trial of BK1803 in pertussis, diphtheria, Tetanus, poliomyelitis, hepatitis B (HBV), sponsored by Mitsubishi Tanabe Pharma. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BK1803
03
Conditions
pertussisdiphtheriaTetanuspoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on NCT07793513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793513.